Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against the off-brand versions, citing safety concerns.
FDA, healthy food
FDA receives reports almost daily from different food companies regarding potential allergens or foodborne illnesses.
Following the recent approval of its Regadenoson generic drug by the United States Food and Drug Administration (FDA), Indies ...
The U.S. Food and Drug Administration (FDA) has announced a final rule updating the definition of the nutrient content claim “healthy.” To qualify ...
The post Shooting the Messenger and Blaming the Victim appeared first on Reason.com.
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...
Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
Attempts to restrict pharmaceutical advertisements have failed many times over the years, often on First Amendment grounds.
The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...
Thanks to new rules implemented by the U.S. Food and Drug Administration (FDA), shoppers at major retailers, including Costco ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback